Mallinckrodt Medical, Inc.

University of Missouri

Other

Mallinckrodt, Inc.

Edward A Deutsch

Dennis L Nosco

Karen F Deutsch

Steven R Woulfe

Robert G Wolfangel

David H White

William H Ralston

Janet B Wilking

William P Cacheris

Mary Marmion Dyszlewski

Linda Meeh

James W Brodack

Mark A DeRosch

William L Neumann

Dennis A Moore

Gary J Ehrhardt

Kathleen M Miller

John Steven Morris

Julie A Beaty

Wilhelmus T Goedemans

Martinus T Maria De Jong

Karen F Libson

Martinus T De Jong

Mark A Derosch

A method of determining providing analytical services, particularly trace element analysis is disclosed. The method includes supplying a sample container to a customer, having the customer return the sample container with the sample inside the container, and analyzing the sample by neutron activation analysis without opening the sample container.

Method of performing analytical services

The present invention relates to the stabilization of radiopharmaceutical preparations and to the stabilization of components of radiopharmaceutical kits. In particular, the present invention relates to stabilization of lyophilized components of radiopharmaceutical kits by the addition of a cyclic oligosaccharide, such as, a modified or unmodified cyclodextrin, to the kit.

Stabilized radiopharmaceutical kits

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for medical diagnostic imaging

The present invention relates to novel radiopharmaceutical imaging agents having non-stannous reductants. The present invention further relates to kits for forming radiopharmaceutical imaging agents, such kits including non-stannous reducing agents.

Radiopharmaceutical formulations having non-stannous reductants

Treated apatite particles are disclosed for enhancing radical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for ultrasound imaging

Treated calcium/oxyanion-containing particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, or tissue disease states is obtained. Depending on the diagnostic imaging technique, calcium/oxyanion-containing particles are treated to be paramagnetic, radiopaque, or echogenic. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described particles and then performing the medical diagnostic procedure.

Treated calcium/oxyanion-containing particles for medical diagnostic

The present invention provides radiation synovectomy compositions for treating inflamed synovium containing a radionuclide complex bound to a hydroxyapatite-like matrix as the radiolabelled synovectomy agent in a sufficient amount to provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, the radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, the radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, the agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.

Radionuclide labelled particles useful for radiation synovectomy

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging (37 MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for x-ray diagnostic imaging

Methods and diagnostic compositions are disclosed for enhancing magnetic resonance imaging which utilize a paramagnetic metal cluster. Magnetic resonance contrast media containing Z.sup.+ [Mn.sub.12 X.sub.12 (OYR).sub.16l (L).sub.4 ].sup.-, where OYR is an oxyacid such as benzoic acid, acetic acid, methyl sulphonic acid, methyl phosphonic acid; L is a neutral donor such as water, alcohol, pyridine, or other amines; X is a chalcogen, such as O or S; and Z is a pharmaceutically acceptable counterion are disclosed. Z may also be a paramagnetic counter ion, such as a high spin metal cluster. The paramagnetic cluster may optionally be complexed or conjugated to a carrier compound capable of altering the paramagnetic metal cluster's biodistribution, increasing its selectivity of tumor localization, and amplifying its proton relaxivity.

Compositions for magnetic resonance imaging using a manganese oxalate

The present invention relates to novel compounds for use as imaging agents. In particular, the present invention relates to imaging agents comprising a heavy metal cluster having 2 to 8 atoms of the same of different heavy metal elements, and at least one coordinating ligand having 1 to 8 atoms which bond to the cluster, and a number of supporting atoms making up the framework of the ligand.

Heavy metal clusters for use as imaging agents

Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol and ascorbic acid to inhibit autoradiolysis of radiolabeled peptides.

Stabilizers to prevent autoradiolysis of radiolabeled peptides and

Process for preparing a radionuclide generator for producing Tc-99m or Re-188. A clear solution containing a metallic cation and an anion comprising W-188 or Mo-99 is provided. The metallic cation is present in the solution as a dissolved complex of the metallic cation and a complexing agent and/or the anion being present in the solution as a dissolved complex of the anion and a complexing agent. The dissolved complex(es) are decomposed to form a slurry containing a precipitate of the metallic cation and the anion. The precipitate is transferred to an elutable container of a radionuclide generator.

Process for the preparation of rhenium-188 and technetium-99m generators

The present invention relates to novel compounds for use as imaging agents. In particular, the present invention relates to paramagnetic metal clusters having oxygen and/or nitrogen containing ligands useful as contrast agents for magnetic resonance imaging (MRI).

Growing community of inventors

Maryland Heights, MO, United States of America

Edward A Deutsch